Narayana Hrudayalaya acquires NewRise Healthcare from Panacea Biotec

Buying a near-complete hospital with around 230 beds to help NH to strengthens its Northern cluster


Dr Devi Prasad Shetty-promoted Narayana Hrudayalaya Limited (NH) has entered into a definitive agreement to acquire NewRise Healthcare Pvt Ltd from Panacea Biotec Limited for an enterprise value of Rs 180 crores. NewRise Healthcare is setting up a multi-speciality, 230-beds hospital at Gurugram, which is in final stages of completion and is expected to be commissioned within the next 9 months. This marks NH’s first hospital in Gurugram.

This transaction is intended to consolidate NH’s footprint in the Northern cluster and therefore serve the region’s fast expanding healthcare space. With a flexible business model, Narayana Hrudayalaya aims to fast-track its penetration and emerge as a prominent healthcare services provider in the growing NCR market.

Located in South-Western part of NCR, NewRise Healthcare complements NH Group’s East Delhi based Dharamshila Narayana Superspeciality Hospital which is presently an oncology focused unit and will be upgraded to a multi-speciality tertiary care unit. This will help create a strong regional network and drive operational synergies.

These recently consummated transactions by NH also emphasise the group’s intention to create a meaningful pan-India presence. These new initiatives will enable Narayana Hrudayalaya to replicate its established business model to newer regions while providing quality and affordable healthcare services.

Commenting on the announcement, Dr Ashutosh Raghuvanshi, vice chairman, managing director and group CEO, Narayana Hrudayalaya Limited, said, “This development is a step forward in the direction towards reinforcing the newly formed Northern cluster. It also echoes our group’s commitment towards developing this region as vibrant as the existing Karnataka and Eastern clusters. We believe our recent ventures in NCR will help us target this key geography more efficiently while accelerating our trajectory to become a true pan-India healthcare service provider.”

Headquartered in Bengaluru, Narayana Hrudayalaya Limited is one of the leading healthcare service providers in India operating a chain of multispecialty, tertiary and primary healthcare facilities. The company has a network of 23 hospitals and 7 heart centres across India and a single hospital overseas at Cayman Islands with over 5,700 operational beds across all its centres with potential to reach a capacity of over 6,900 beds.

Source: http://www.business-standard.com/content/b2b-pharma/narayana-hrudayalaya-acquires-newrise-healthcare-from-panacea-biotec-117042100687_1.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more